IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections

Oct. 21, 2026

Shionogi & Co., Ltd. will present new data at IDWeek 2026 that reinforce the role of Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in serious Gram-negative infections.

Shionogi Press Release
Share:
A Shionogi Group Company